Answers are grounded in this paper and cite their sources.
The Next Phase of Human Gene-Therapy Oversight As gene therapy continues to change, so must the federal framework set up to oversee it. As new biotechnologies continue to emerge, the NIH and the FDA are proposing reductions in duplicative oversight and changes to the role of the Recombinant DNA Advisory Committee.
No takes yet. Share an insight, caveat, or question.
Collins et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: